Research on chemotherapy and its side effects. Covers nerve-injury prevention, gold-nanorod therapy, less-intensive regimens, and combination treatments.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Studies on hypofractionated postmastectomy radiotherapy, proton therapy for hepatocellular carcinoma, and stereotactic body radiation therapy for Ewing sarcoma showcase improved patient outcomes. The findings also suggest potential benefits for short-course radiation therapy access and patient navigation in cancer centers.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
A new trial will determine whether chemotherapy provides additional benefit for patients with high anatomic risk but low genomic risk. The RxFINE-Low trial will enroll 2,000 postmenopausal women and men with high anatomic risk breast cancer and low genomic risk, and follow them for up to 10 years.
A new study reveals that childhood chemotherapy can cause DNA damage in healthy tissues, including the liver, leading to increased health risks later in life. The research, published in Science, found that platinum-based chemotherapy drugs can 'age' children's healthy cells, causing DNA changes similar to those seen in adult tissues.
The study confirms the durability of benefit for pembrolizumab plus chemotherapy as a first-line standard-of-care option for recurrent and metastatic cervical cancer. This treatment regimen has been shown to provide a significant advantage over traditional chemotherapy in patients with this type of cancer.
Researchers discovered that psilocybin prevents nerve injury and associated symptoms in preclinical models, protecting sensory nerve endings and preserving touch sensation. Psilocybin may offer a new intervention for preventing chemotherapy-induced peripheral neuropathy, improving patients' quality of life.
A phase 2 clinical trial found that a less-intensive combination of azacitidine and venetoclax was more effective in treating acute myeloid leukemia, with patients tolerating treatment better and spending less time in the hospital. The combination also led to more patients reaching stem cell transplantation.
Researchers at IIT Gandhinagar develop a gold nanorod-based platform for ER-targeted cancer treatment, combining targeted drug delivery with photothermal therapy. The approach induces ER stress-mediated autophagy and apoptosis in cancer cells.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
Scientists at MUSC Hollings Cancer Center discovered a protein called lysyl oxidase that helps triple-negative breast cancer cells survive. Blocking LOX creates a weakness, which can be exploited with a second drug to block tumor growth without chemotherapy.
Researchers have developed an oral therapy that protects healthy tissue from radiation while preserving radiation's ability to destroy cancer cells. The therapy, called XOlacta, is packaged in milk-derived extracellular vesicles and can be administered orally, reducing damage to tissues and preserving tumor treatment effectiveness.
A nationwide claims data analysis in Japan found breast cancer survivors have a 1.57-fold higher risk of herpes zoster and a 1.70-fold higher risk of postherpetic neuralgia. Vaccination can reduce both the incidence of herpes zoster and the risk of complications, emphasizing the importance of prevention in breast cancer survivorship care.
Researchers found that tumors can damage peripheral nerves before chemotherapy begins, leading to potential nerve damage and chronic pain. The study challenges the conventional thought that peripheral neuropathy is mostly due to chemotherapy treatment.
A new study at Durham University has found that combinations of heavy metals can make lung cancer cells resistant to chemotherapy. However, the resistance can be reversed with a metal-removal treatment called MiADMSA, which has the potential to improve treatment outcomes and reduce side effects.
A study published in JAMA Otolaryngology–Head & Neck Surgery found that preoperative chemo-immunotherapy was more effective than immunotherapy alone in reducing tumor size in patients with head and neck cancer. The study analyzed data from 86 adults with head and neck cancer treated between July 2024 and March 2026, and showed that pat...
A randomized phase 3 study found that first-line osimertinib plus chemotherapy significantly improved median progression-free survival compared to osimertinib alone in patients with advanced non–small cell lung cancer (NSCLC) and concurrent EGFR and TP53 mutations. This study provides evidence for incorporating TP53-based molecular ris...
Researchers have developed an experimental drug that tricks cancer cells into consuming more sugar than usual, then blocks their backup fuel source – fat. This approach puts cancer cells under so much stress that many die, demonstrating effectiveness in treating aggressive melanoma in mice.
A rare case of uterine carcinosarcoma was reported, characterized by a dual molecular signature that may refine prognosis and guide treatment decisions. The patient's tumor displayed a high-grade endometrioid homologous uterine carcinosarcoma with TP53 and MSH6 genetic alterations.
A study found that reshaping the gut microbiome with antibiotics can significantly reduce liver clearance and double chemotherapy delivery to tumors. This approach has potential as a strategy to enhance nanoparticle-based cancer drugs.
Combining cemiplimab, fianlimab, and paclitaxel-based neoadjuvant chemotherapy improved pathologic complete response rates in high-risk -negative breast cancer. Patients with the ImPrint immune signature showed enhanced sensitivity to the combination.
A new study found that fructose increases the spread of aggressive ovarian cancer by suppressing cholesterol production in neighboring cells. This discovery raises the possibility that simple dietary changes could influence cancer progression and potentially lead to new treatment strategies.
Researchers analyzed over 600 tumors from 544 patients and found distinct genomic signatures of DNA changes linked to different chemotherapies. These patterns appeared as early as 91 days after treatment began, allowing clinicians to track treatment-resistant tumours and potentially reduce toxic effects. The study could lead to a more ...
Researchers found that chemotherapy triggers an inflammatory cascade recruiting immune cells to protect the tumor, leading to chemoresistance. Blocking this pathway with existing drugs may restore chemotherapy sensitivity.
Researchers identify a promising new strategy to overcome drug resistance in deadly brain cancer by blocking nitrosative stress. Combining BA-101 with temozolomide slows tumor growth, reduces cancer's ability to spread, and increases cancer cell death.
A new strategy makes stem cell transplants safer by replacing chemotherapy-based treatment with targeted antibodies that recognize specific markers on blood-forming stem cells. This approach allows for less toxic treatment and could enable chemotherapy-free or chemotherapy-sparing transplantation approaches.
Researchers at the University of Warwick and Monash University have uncovered a molecular basis for combinatorial biosynthesis, a strategy to create multiple versions of powerful cancer therapies. By understanding how bacterial enzymes interact, they can design new therapies with improved potency and selectivity.
A University of Arizona research team has developed a nanotechnology-based platform combining paclitaxel with siRNA to enhance the immune response against lung cancer. The approach exploits an 'eat me' signal on dying cancer cells, attracting immune cells and initiating tumor death.
Researchers have identified immune markers that can help doctors determine which breast cancer patients are unlikely to benefit from chemotherapy. The new AI-based method analyzes the body's own immune cells found near a tumor, providing additional insight to identify patients who can safely have chemotherapy withheld.
Researchers at Salk Institute uncover an unexpected role for HDAC enzymes in controlling critical genes involved in DNA repair, making pancreatic cells more vulnerable to therapies that induce DNA damage. This finding paves the way for new treatment strategies combining entinostat with DNA-damaging therapies.
Researchers at UT MD Anderson Cancer Center have achieved high response rates in patients with hard-to-treat acute myeloid leukemia (AML) using an all-oral combination therapy. The study also provides insights into the origins of cancer, revealing that tumors evolve rapidly through bursts of genetic changes.
The study found that adjuvant nivolumab did not improve disease-free survival in patients with resected non–small cell lung cancer. The treatment was also not effective in sensitizing EGFR and ALK alterations.
A new study reveals that nitrosylcobalamin, a vitamin B12 analog, selectively crosses the blood-brain barrier and targets glioblastoma tissue, demonstrating broad antitumor activity. The therapy also shows synergistic activity with existing treatments, offering a promising new strategy for treating this deadly brain cancer.
Researchers found that increasing ADAR2 expression in osteosarcoma cells forces them to differentiate, slowing growth and invasive capacity. The treated cells began producing mineralized matrix, a hallmark of mature bone tissue. In mice, ADAR2-restored tumors were smaller and less invasive.
A new study reveals that the cancer-causing protein MYC plays a direct role in fixing damaged DNA in tumor cells. This allows cancer cells to survive chemotherapy and other treatments, contributing to tumor resistance and poor patient outcomes. The findings could lead to new therapies targeting MYC's repair function.
Researchers at UT MD Anderson Cancer Center have made significant advancements in cancer care, including the development of a targeted RAS inhibitor therapy for pancreatic cancer and a biomarker of chemotherapy resistance in relapsed lung cancer. The studies also explore the tumor microenvironment of triple-negative breast cancer and i...
Researchers developed a 13-gene panel and machine learning model to predict TNBC patient responses to chemotherapy, identifying macrophage subtypes associated with treatment outcomes. The study provides novel insights into the gene-expression programs and tumor microenvironment of early-stage triple-negative breast cancer.
Researchers have identified a hidden mechanism explaining why breast cancer can return years after successful treatment. Slow-growing breast cancer cells can form microscopic tumours that silently tick away in distant organs, evading detection for decades.
Researchers at UT MD Anderson Cancer Center have made significant advancements in targeted therapy treatments for advanced lung cancer and early-stage classical Hodgkin lymphoma. The studies showcase high response rates with novel combination therapies and a new understanding of how an enzyme affects infertility and cancer progression.
Researchers have discovered a biomarker for chemotherapy resistance in small cell lung cancer, which can help identify cells that become more invasive and lead to treatment resistance. Targeting these cells with YAP1 may be a possible strategy to improve patient outcomes.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
A study published in PLOS Medicine found that age at initial diagnosis, sex, and type of first cancer significantly affect the risk of developing a subsequent primary cancer. Older age and male sex were associated with a higher risk, while survivors of lung, bladder, and skin melanoma were also at increased risk.
Binghamton University Professor L. Nathan Tumey is working on developing new chemical technologies for antibody-drug-conjugates to push the boundaries of what can be accomplished in ADCs. The goal is to awaken tumor-associated immune cells and prevent cancer regrowth.
The Alliance for Clinical Trials in Oncology has several active trials specifically designed to help people with head and neck cancers. Trials include testing high-dose prophylactic gabapentin to prevent opioid use during treatment, as well as immunotherapy with nivolumab and cabozantinib for mucosal melanoma and nasopharyngeal carcino...
A Phase II trial found that exercise can improve cognitive function in patients receiving chemotherapy, while low-dose ibuprofen may also have some benefits. The study suggests that exercise is more effective in improving cognitive outcomes, but further research is needed to explore the effects of ibuprofen and combination therapy.
Researchers from UT MD Anderson Cancer Center present studies on single-cell technologies, integrative computational approaches, and experimental therapeutics, highlighting innovations in mRNA vaccines and spatial multi-omics techniques. The studies aim to improve immunotherapy responses and detect treatment-resistant glioma cells.
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
A randomized trial found that duloxetine does not prevent painful neuropathy caused by oxaliplatin-based chemotherapy in patients with stage II or III colorectal cancer. The study suggests that duloxetine should only be used for managing existing neuropathy, not prevention.
A study from Japan has revealed a gradual increase in tAML rates, especially after breast cancer treatment. The study analyzed data from the Osaka Cancer Registry and found that the annual incidence of tAML increased from 0.13 to 0.36 per 100,000 population between 1990 and 2020.
A study found that tumor DNA in patients' blood can predict whether breast cancer will return, especially after neoadjuvant treatment. Patients with detectable DNA at the end of treatment were 3.5 times more likely to relapse during follow-up.
Researchers found that NUTM1 rearranged leukemia is distinct from other forms, with decreased DNA methylation and increased lifespan of blood cells. Leukemias with BRD9-NUTM1 fusion are extremely sensitive to chemotherapy, leading to improved clinical outcomes.
The phase III Alliance ATOMIC trial shows that adding immunotherapy to standard chemotherapy improves clinical outcomes for patients with stage III dMMR colon cancer. The study found a 50% reduction in cancer recurrence risk and a 86.3% disease-free survival rate at three years.
A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.
A randomized crossover pilot study found that pre-chemotherapy exercise can reduce cancer-related fatigue and attenuate symptoms. High-intensity interval exercise performed before treatment showed significant benefits on Day 5 post-chemotherapy.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
A phase 3 clinical trial found romiplostim significantly reduced chemotherapy dose delays and improved platelet counts in patients with gastrointestinal cancers who developed persistent low platelet counts during treatment. The therapy enables patients to maintain chemotherapy intensity, potentially preserving the integrity of cancer c...
Researchers have identified and resolved molecular bottlenecks to produce doxorubicin, a vital chemotherapy agent, resulting in a 180% increase in production. This breakthrough enables cost-effective manufacturing of essential antibiotics and anti-cancer agents, promising a cleaner and more reliable supply of life-saving medicines.
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Researchers found that patients who followed an exercise prescription while receiving chemotherapy reported fewer problems with thinking and memory and felt less mentally tired. The study suggests that exercise may help people with cancer stay mentally sharp and better able to handle daily tasks.
A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.